tiprankstipranks
Advertisement
Advertisement
Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
PremiumCompany AnnouncementsImmutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
1M ago
Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease
Premium
The Fly
Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease
1M ago
Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
Premium
Company Announcements
Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
1M ago
Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study
PremiumThe FlyImmutep says IDMC recommends discontinuation for TACTI-004 Phase III study
1M ago
Immutep downgraded to Neutral from Outperform at Baird
Premium
The Fly
Immutep downgraded to Neutral from Outperform at Baird
1M ago
Immutep downgraded to Market Perform from Outperform at Citizens
Premium
The Fly
Immutep downgraded to Market Perform from Outperform at Citizens
1M ago
Immutep Secures Dr. Reddy’s Licensing Deal and Reports Strong Q2 FY26 Clinical and Cash Progress
PremiumCompany AnnouncementsImmutep Secures Dr. Reddy’s Licensing Deal and Reports Strong Q2 FY26 Clinical and Cash Progress
3M ago
Immutep reports Q2 cash receipts from customers A$4,000
Premium
The Fly
Immutep reports Q2 cash receipts from customers A$4,000
3M ago
Immutep Reports Positive Phase I Data for First-in-Class Autoimmune Antibody IMP761
Premium
Company Announcements
Immutep Reports Positive Phase I Data for First-in-Class Autoimmune Antibody IMP761
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100